Work

Exploiting HLA-II Promiscuity via Peptide Terminal Overhang Recognition for Pan-Allelic and Tumor-Selective AML Immunotherapy

Year: 2026

Type: preprint

Source: bioRxiv (Cold Spring Harbor Laboratory)

DOI: 10.64898/2026.03.01.708866

Authors: Saori Fukao, Evey Y. F. Zheng, Fumie Ihara, Yukiko Matsunaga, Yota Ohashi, Dong-Hoon Han, Xinyu Wei, Kana Hasegawa, Brian D. Burt, Kayoko Saso, Dalam Ly, Marcus O. Butler, Mark D. Minden, Yuki Kagoya, Naoto Hirano

Institutions: University Health Network, Princess Margaret Cancer Centre, University of Toronto, Keio University, University of Hong Kong

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Canadian Institutes of Health Research

Award: Canadian Program of Research on Ethics in a Pandemic (CanPREP): Whose risks, whose duties, and what priorities?

OpenAlex ID: W7133336764

Cites: 63

Cited by:

Related to: 10